A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19.

ABSTRACT:

Background

Lymphopenia and failure of lymphocytes to mount an early IFN-γ response correlate with increased mortality in COVID-19. Given the essential role of CD4 helper and CD8 cytotoxic cells in eliminating viral pathogens, this profound loss in lymphocytes may impair patients' ability to eliminate the virus. IL-7 is a pleiotropic cytokine that is obligatory for lymphocyte survival and optimal function.

Methods

We conducted a prospective, double-blind, randomized, placebo-controlled trial of CYT107, recombinant human IL-7, in 109 critically ill, patients with lymphopenia who have COVID-19. The primary endpoint was to assess CYT107's effect on lymphocyte recovery with secondary clinical endpoints including safety, ICU and hospital length-of-stay, incidence of secondary infe

SUBMITTER: Shankar-Hari M 

PROVIDER: S-EPMC11949036 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature